The Efficacy of Fluticasone and Salmeterol 250/50μg Daily Inhalation Combination Compared to Budesonide 800μg Daily Inhalation to Control Moderate Persistent Asthma
| Main Authors: | Megantara, Megantara; Faculty of Medicine University of Indonesia, Persahabatan Hospital, Jakarta, Yunus, Faisal; Faculty of Medicine University of Indonesia, Persahabatan Hospital, Jakarta, Wiyono, Wiwien Heru; Faculty of Medicine University of Indonesia, Persahabatan Hospital, Jakarta |
|---|---|
| Format: | application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
Journal of the Indonesian Medical Association
, 2010
|
| Online Access: |
http://indonesia.digitaljournals.org/index.php/idnmed/article/view/899 |
Daftar Isi:
- The aim of the study was to elucidate the difference in clinical manifestation, FEV1 and quality of life between inhaled fluticasone/salmeterol and inhaled budesonide on moderate persistent asthma. This was a prospective, comparative (parallel), randomized and double open trial. The subject consisted of patients with moderate persistent asthma based on GINA 2005 criteria who came to Asthma Clinics Persahabatan Hospital Jakarta, aged 12-65 year and normal laboratory exavination. Subjects were divided into 2 groups. Group 1 was treated with budesonide inhalation and group 2 was treated with fluticasone/salmeterol inhalation. This study showed that the fluticasone/salmeterol group had better improvement FEV1, AQLQ score, wheezing disorder, reliever usage score than the budesonide group. Beside the variables stated above, this study also showed change the frequency of cough, limitation of daily activities and nocturnal symptoms. Although both of group showed no statistically no significant difference but the fluticasone/salmeterol group showed better improvement compared to the budesonide group. We concluded that fluticasone/salmeterol was better in controlling asthma with better clinical manifestation, FEV1 and quality of life compared to the budesonide group.Keywords: Moderate persistent asthma, clinical manifestation, FEV1, AQLQ